GlassScriptPhysician profile
Kayellen Willoughby
NPI 1386678118
$3,930.41
in general payments reported to CMS, 2019-2025
31 companies · $722 in 2025
The $722 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $678 · 2021: $45.95 · 2022: $439 · 2023: $865 · 2024: $536 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $502.22 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $456.77 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $409.91 | 2022-2025 | Repatha, Krystexxa, Otezla |
| Pfizer INC. | $356.08 | 2019-2025 | |
| Gilead Sciences, INC. | $289.75 | 2019 | |
| Paratek Pharmaceuticals, INC. | $282.42 | 2023-2024 | Nuzyra |
| Allergan, INC. | $277.19 | 2019-2020 | |
| Glaxosmithkline, LLC. | $266.58 | 2019-2024 | Shingrix, Arexvy, Menveo |
| Genentech USA, INC. | $186.56 | 2019-2020 | |
| Abbvie INC. | $181.49 | 2023 | Creon, Vraylar, Ubrelvy |
| Esperion Therapeutics, INC. | $101.40 | 2020 | |
| Galderma Laboratories, L.P. | $88.79 | 2019 | |
| Novo Nordisk INC | $85.51 | 2020 | |
| Merck Sharp & Dohme LLC | $47.32 | 2019-2024 | Capvaxive |
| Seqirus USA INC | $40.82 | 2023-2025 | Fluad, Flucelvax Quadrivalent, Fluad Quadrivalent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.78 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.07 | 2025 | |
| Exact Sciences Corporation | $31.68 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi Pasteur INC. | $25.90 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.28 | 2020 | |
| Eisai INC. | $22.88 | 2022 | |
| Irhythm Technologies, INC. | $21.57 | 2022 | |
| Axsome Therapeutics, INC. | $21.18 | 2023 | Auvelity |
| Antares Pharma, INC. | $18.50 | 2024 | Xyosted |
| Janssen Pharmaceuticals, INC | $15.32 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2024 | Zoryve |
| Astellas Pharma US INC | $14.95 | 2023 | Myrbetriq |
| Idorsia Pharmaceuticals US INC | $14.18 | 2024 | Quviviq |
| Shire North American Group INC | $12.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayellen Willoughby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.